Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cannabidiol 1 by Cardiol Therapeutics for Pericarditis: Likelihood of Approval
Cannabidiol 1 is under clinical development by Cardiol Therapeutics and currently in Phase II for Pericarditis. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Cardiol Therapeutics's Cannabidiol 1?
Cannabidiol 1 is a small molecule commercialized by Cardiol Therapeutics, with a leading Phase II program in Pericarditis. According to...
Cannabidiol 1 by STERO Biotechs for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Cannabidiol 1 is under clinical development by STERO Biotechs and currently in Phase II for Crohn's Disease (Regional Enteritis). According...